This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Wilex AG

Drug Names(s): WX-G250, cG250, girentuximab

Description: Rencarex is a highly specific IgG1 monoclonal antibody that targets the antigen carbonic anhydrase IX (CA IX, MN, or G250 antigen). MN/CA IX is a cell surface antigen expressed in over 90% of all clear cell RCC, but not expressed in normal kidney tissue. In normal tissue the antigen is expressed at low levels and restricted to the gastric epithelium, upper intestinal tract epithelium, and the bile ducts, but is undetected in normal kidney and other tissues. Rencarex binds to the MN/CA IX antigen expressed on the tumour cells, thereby triggering an immune reaction called Antibody-Dependent Cellular Cytotoxicity (ADCC). Through this mechanism, effector cells, e.g. NK (natural killer) cells, of the immune system are activated to kill the tumour cells.

Deal Structure: Wilex & JNJ
In August 1999, Wilex announced that it has acquired an exclusive licence from Centocor for G250. Under the agreement Wilex will develop the antibody and conduct clinical trials for its use in the treatment of renal cell carcinoma, while Centocor will retain an option for product marketing rights in the U.S. If Centocor exercises this option, Wilex will receive upfront and milestone payments and will share profits.

Wilex & Bayer
In November 2001, Wilex announced that it had entered into a license, sublicense and option agreement with Bayer Corporation's Business GroupDiagnostics to obtain certain rights under Bayer's MN patent portfolio. Through this agreement Wilex receives certain intellectual property rights which protect its G250 antibody.

Esteve & Wilex
In April 2004, Wilex and Laboratorios del Dr. Esteve (Esteve) announced that they signed a co-development and marketingagreement for Wilexs Rencarex in Southern Europe. Under the...See full deal structure in Biomedtracker

Partners: Esteve, S.A. Bayer AG Johnson & Johnson

Rencarex News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug